verified SJR 1,13 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Elsevier Inc.

workspace_premium Q1 — Oncology lock Subscription

Clinical Genitourinary Cancer

Clinical Genitourinary Cancer is a journal indexed in SJR in Oncology and Urology with an H index of 59. It has a price of 3047 €. It has an SJR impact factor of 1,13 and it has a best quartile of Q1. It has an SJR impact factor of 1,13.

ISSN: 1558-7673

Publisher: Elsevier Inc.

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,13 Q1

H-index 59

Acceptance rate pie_chart

31%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.047 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,13

H-index

Docs (year)

289

Docs 3y

449

Total refs

8924

Cites 3y

1209

Citable 3y

441

Cites/Doc 2y

2.64

Ref/Doc

30.88

Immediate OA

3047 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

What Constitutes High-Risk Locally Advanced Prostate Cancer?

Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study

Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer

Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors

Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer

Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T

Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy

Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center

Classification of Histologic Patterns of Pseudocapsular Invasion in Organ-Confined Renal Cell Carcinoma

Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer

Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study

SHOW MORE ARTICLES

Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel

A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer

Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI

Advanced Prostate Cancer 2010: What a Year!

Adjuvant Versus Neoadjuvant Androgen Deprivation With Radiotherapy for Prostate Cancer: Does Sequencing Matter?

Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature

Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer

Acquired Hemophilia Caused by Ureteral Tumor

A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite

A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)

A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer

A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature

FAQs

Clinical Genitourinary Cancer has an SJR of 1,13 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3047 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Clinical Genitourinary Cancer is 31%.

Clinical Genitourinary Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Clinical Genitourinary Cancer?

What is the APC / publication cost?

What is the acceptance rate?